Why the study?
Cardiovascular dysfunction is a frequent and severe complication in septic shock with unclear physiopathologic mechanisms and limited treatment options.
Does levosimendan improve acute hemodynamic effects in septic patients with severe cardiovascular dysfunction?
Does levosimendan improve acute hemodynamic effects in septic patients with severe cardiovascular dysfunction?
This abstract outlines a study aiming to evaluate the acute hemodynamic effects of levosimendan in septic patients with severe cardiovascular dysfunction, but provides no results.
Cardiovascular dysfunction (CD) occurs frequently among patients with septic shock and it is more severe in the first 3 days, relapsing at the end of the first week among those who survive. Fifteen percent of the patients with septic shock, who evolve to death, die as a result of CD, whose physiopathologic mechanisms are not fully understood. Levosimedan (LEVO), a new inotropic drug which acts as calcium sensitizing agent and also has effects on potassium channels in vascular smooth muscle cells leading to vasodilatation action, has shown benefits in patients with cardiac failure. An experimental study on the endotoxic shock model has shown improvement on cardiac output, and systemic and regional oxygenation. The aim of this study is to prove the acute hemodynamic effects of LEVO administration on septic patients with severe CD.
No takes yet. Share an insight, caveat, or question.
Rezende et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: